Thomas Marron, MD, PhD
- ASSISTANT PROFESSOR | Medicine, Hematology and Medical Oncology
- Cancer (Oncology)
- Hospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Morningside and Mount Sinai West
- The Mount Sinai Hospital
- Ruttenberg Treatment Center 212-241-6756 212-241-6756
Thomas Marron, MD, PhD, is Assistant Director of Immunotherapy and Early Phase Trials at The Tisch Cancer Institute and Assistant Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai.
As a member of the Center for Thoracic Oncology, Dr. Marron treats thoracic malignancies, including non-small cell lung cancer, small cell lung cancer, and malignant pleural mesothelioma. He leads numerous clinical trials for thoracic malignancies and hepatocellular carcinoma (liver cancer). He also leads the Phase 1 trials program at The Mount Sinai Hospital, where he enrolls patients into dozens of trials focused on development of novel cancer immunotherapies.
As a member of The Tisch Cancer Institute and the Precision Immunology Institute, Dr. Marron works closely with basic scientists across the Mount Sinai Health System, translating preclinical findings into clinical advances. He leads a large translational neoadjuvant program focused on clinical trials for multiple types of cancer. The goal of these trials is to decrease the likelihood that cancer will return after surgery; in parallel, they support deep interrogation of the effect of new and standard therapies on the tumor immune microenvironment at the single-cell level. Further, the trials enable Dr. Marron and collaborators to define combination approaches that optimize response rates and the durability of novel immune-based therapies, while minimizing toxicity.
MD,PHD, Mount Sinai School of Medicine
Residency, Internal Medicine
Mount Sinai Hosptial
Fellowship, Medical Oncology
Mount Sinai Hospital
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Marron during 2020 and/or 2021. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
Scientific Advisory Board:
- Boehringer Ingelheim Corporation
- Genentech, Inc.
- Regeneron Pharmaceuticals
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.